The recognition highlights a department that manages more than 5,000 procedures annually, spanning brain tumor resections, complex spinal disorders, and cerebrovascular interventions. By integrating advanced neuroimaging with intraoperative functional monitoring, the surgical teams aim to maximize tumor removal while preserving critical patient functions. The hospital further incorporates artificial intelligence into its clinical workflows to accelerate decision-making for intracranial hemorrhages and traumatic brain injuries.

Beyond traditional surgery, the institution is gaining attention for its work in regenerative medicine. Central to this is the CAR001 clinical trial, an allogeneic CAR gamma delta T-cell therapy developed alongside Ever Supreme Bio Technology. While the treatment remains investigational, early results have shown significant promise in patients with recurrent glioblastoma—a condition typically associated with limited survival windows. Looking forward, the hospital plans to scale its research into exosomes and mitochondrial medicine, targeting chronic conditions such as Parkinson’s and Alzheimer’s disease as it seeks to establish Taiwan as a hub for homegrown medical innovation.